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Abstract
Background: Female breast cancer is known as one of the top five cancers in terms of mortality. Regarding contradictory reports
about the mortality trend of this cancer and its association with the socio-economic status of the world countries, we aimed at
assessing the global trend of female breast cancer mortality rate and investigate the relationship between its mortality rate and
development status.
Methods: The breast cancer Age Standardized Mortality Rate (ASMR) per 100,000 and Human Development Index (HDI) for 179 world
countries were extracted, respectively from the Global Burden of Disease (GBD) 2017 study and the United Nations Development
Programme (UNDP) database, for the period 1990 to 2017. The marginal modeling methodology was employed to analyze the global
trend of ASMR and examine the relationship between ASMR and HDI.
Results: The results showed a slightly constant curve for the global trend of breast cancer ASMR from 1990 to 2017 (around 17 per
100,000). Moreover, it was indicated that the ASMR is strongly related to development status. While countries with higher levels of
HDI have experienced a declining trend of breast cancer mortality rate, countries with lower HDI levels experienced an ascending
trend at this period.
Conclusions: In general, the findings showed that mortality due to breast cancer is still a major health problem in total world
countries. Hence, more efforts should be made to screen the patients in the early stages of the disease and promote the level of care,
especially in countries with lower levels of economic development.
Keywords: Breast Neoplasm, Mortality
1. Background
Breast cancer as a global public health problem is the
most common cancer (1) and the second most prevalent
cause of death by cancer in females worldwide (2). In
2016, there were about 1.7 million incident breast can-
cer cases and 535,000 deaths from this disease in women
throughout the world (3). Also, it caused about 1.5 million
Disability-Adjusted Life Years (DALYs) for women in the year
2016 (4). Although more than half of the global burden
of this disease is currently experienced in developed coun-
tries, it has been reported that the incidence and preva-
lence rates are remarkably rising in developing countries
(1). The result of a systematic analysis suggests that despite
the global efforts for primary prevention of breast cancer,
only 20% to 50% of this disease can be prevented (4).
In recent years, although the survival rate of patients
with breast cancer shows an improving trend, the regional
and global reports indicate that prevalence and incidence
of this cancer are increasing both in developed and devel-
oping countries (5). In the United States, for example, there
is an estimated 16% increase in new cases of females with
breast cancer from 2015 to 2019 (from 231,840 cases in 2015
to 268,600 cases in 2019). In the same interval, the esti-
mated deaths from this cancer in women have shown an
increase of 3.6% (from 40,290 deaths in 2015 to 41,760 cases
in 2019) (6, 7). From 1990 to 2016, the global female deaths
due to breast cancer increased by about 60%, while the age-
standardized mortality rate had a reduction of 15% (5). Al-
though factors like aging, overweight or obesity, genetic,
early menarche age, first child birth after 30 years, lifestyle
changes, and ethnicity have previously been identified as
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the related indicators of breast cancer (8), the death from
breast cancer is known to be statistically associated with
some other factors such as detecting the cancer in the late
stages, lack of access to proper treatment, and low socio-
economic status (9). In this context, some researchers be-
lieve that the Human Development Index (HDI), as a key in-
dicator of the socio-economic status of world countries, is
significantly related to breast cancer mortality.
In our literature review, we found some published
studies about the relationship between death from breast
cancer and HDI in different parts of the world. For instance,
Hu et al. have used the Global Cancer Incidence, Mortal-
ity, and Prevalence (GLOBOCAN) 2012 database and con-
cluded that there is a negative significant correlation be-
tween mortality to incidence ratio and national HDI (10).
In a study on the Global Burden of Disease (GBD) 2016
data, it has been shown that breast cancer incidence, mor-
tality, and mortality-to-incidence ratio are significantly re-
lated to HDI. In the above study, using the simple pairwise
correlation coefficient, it has been demonstrated that the
breast cancer mortality rate in countries with low/medium
HDI is significantly higher than high/very high HDI coun-
tries (5). However, some other studies that showed no
significant association between these indices. In a cross-
sectional study, Ghoncheh et al. assessed the association
between incidence and mortality of breast cancer and HDI
in 2012. They have reported no significant correlation be-
tween age-specific incidence and mortality rates and HDI
(11). A more detailed review of the previously conducted
studies in this field reveals two important shortages; first,
almost all of these studies have used simple and univari-
ate statistical methods for analyzing the data. Although
a wider range of readers are familiar with the classic and
easy-to-understand univariate tests, these types of statisti-
cal analysis may lead to misleading results when the avail-
able data has a multivariate nature. Second, all the pub-
lished articles have investigated the cross-sectional rela-
tionship between breast cancer mortality rate and HDI. As
we know, both the breast cancer mortality rate and HDI
have a longitudinal nature (the annual estimate of these
indices is not a constant value for each world country),
thus assessing the association between these indices in a
cross-sectional framework seems not be a proper choice.
2. Objectives
Regarding the mentioned controversial results and
the above-mentioned shortages in the previous studies in
this field, we conducted the present study for analyzing
the GBD data, using more advanced statistical methods
to achieve two goals; first, to analyze the global trend of
breast cancer mortality rate from 1990 to 2017, and second,
to investigate the longitudinal relationship between HDI
and age-standardized breast cancer mortality rate in the
described period of time.
3. Methods
The ethical aspect of the present study was
approved by the Ethics Committee of Shahid Be-
heshti University of Medical Sciences (Ethics code:
IR.SBMU.RETECH.REC.1397.654).
3.1. GBD Data Set
The GBD uses available data to estimate some key in-
dices such as mortality, prevalence, incidence, and DALY
rates for both sexes, different age groups, and 195 world
countries. These health indices can help policymakers to
have a better realization about the current and future chal-
lenges in their territories. A group of more than 3,600 re-
searchers collect and analyze the GBD data which enables
us to make statistical inferences among populations over
time. The GBD data sets include vital and sample registra-
tion systems, household surveys, censuses, and other de-
mographic statistics. The GBD study is perfectly in agree-
ment with suggestions from Guidelines for Accurate and
Transparent Health Estimates Reporting statement. In this
study, we used the GBD data for female breast cancer age-
standardized mortality rate (ASMR) in 195 countries world-
wide from 1990 to 2017. All rates are reported per 100,000
person-years. To compute the age-standardized rates, the
GBD world population standard was utilized (12, 13).
Here it should be noted that both the GBD and World
Health Organization (WHO) provide databases related to
the burden of disease in different parts of the world. In the
present study, we preferred to use the data from the GBD
website because it contains data for nearly all world coun-
tries. The GBD data sets are estimated using information
from four potential sources including annual case notifi-
cations, expert judgment on the case detection, prevalence
surveys, and cause of deaths data which makes them more
reliable and comprehensive than the WHO estimates.
3.2. HDI Data Set
The HDI, which was first published in 1990 as an al-
ternative to conventional assessment of development, is
a statistical index to evaluate social and economic condi-
tions of world countries. Using this index, the countries
can be ranked by their achievement levels of human de-
velopment. For calculating HDI, three indicators are uti-
lized: life expectancy at birth as the health indicator ex-
pected years of schooling for school-age children and aver-
age years of schooling in the adult population as the educa-
tional indicator, and growth national income per capita as
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the economic indicator. There are four levels for HDI: low
HDI (values between 0.350 and 0.554), medium HDI (values
between 0.555 and 0.699), high HDI (values between 0.700
and 0.799), and very high HDI (values 0.800 and 1). The HDI
data is available in the United Nations Development Pro-
gramme (UNDP) Website (14).
3.3. Statistical Analysis
For descriptive purposes, we summarized the ASMR
data by mean ± SD and represented the mean trend of
rates using the line plots. For analytic purposes, since
repeated measures (longitudinal) ASMR observations for
each country are available from 1990 to 2017, the marginal
modeling and Generalized Estimating Equations (GEE)
(GEE) methodology was applied. More formally, we fitted
the following marginal model to investigate the time trend
of ASMR, separately in each level of HDI:
(1)µij = β0 + β1 timeij
where µij shows the mean ASMR for the ith country in
the jth year under the study (i = 1, 2, …, 175 and j = 0, 1, …,
27). The time covariate denotes the study time point (time
= 0, 1, …, 27 as a proxy for year = 1990, 1991, …, 2017). In ad-
dition, when the mean ASMR trend has not a linear form,
the above-mentioned marginal model needs some correc-
tions to capture this non-linearity in the data. In the sim-
plest form, for instance, when a single knot is observable at
time t* in the mean trend plot, the following linear spline
model can be fit to the data:
(2)µij = β0 + β1 timeij + β2(timeij − t∗)+
where the covariate (timeij − t∗)+ = 0 if time ≤ t*
and (timeij − t∗)+ = timeij − t
∗ if timeij > t*. Finally,
to estimate the model parameters, an unstructured corre-
lation model was used (15, 16). The interpretation of the
estimates is exactly similar to the common simple linear
regression model parameters. More formally, the parame-
ter β1 in models (1) and (2) indicates the annual change of
mean ASMR for all world countries. The data analysis was
performed in the R software (version 3.0.2) and the P values
less than 0.05 were considered statistically significant.
4. Results
In this study, we analyzed the ASMR and HDI data from
179 world countries (some countries were not included in
the analysis due to incomplete HDI data). Table 1 shows
the descriptive statistics for the mortality rates in some se-
lected years by the HDI level. Regarding the last row of
Table 1 (total world countries), the breast cancer mortal-
ity rate had a rather steady trend between 1990 and 2017
(started from about 17.06 per 100,000 in the year 1990 and
reached to 17.07 per 100,000 in the year 2017). Figure 1 dis-
plays the trend of breast cancer mortality rate for all coun-
















































































Figure 1. Mean trend of breast cancer ASMR for total world countries
In the next step of data analysis, we used a longitudi-
nal approach to model the behavior of the observed trend
in Figure 1. Regarding the non-linear shape of the mean
breast cancer ASMR trend in this figure (presence of a knot
in the year 1995), we fitted the spline model described in
the Methods section with t* = 5 to the data. Table 2 shows
the obtained results.
In Table 2, one can observe that the world countries
have about 17 per 100,000 deaths in 1990 (estimate of the
model intercept) followed by a positive slope of 0.157 un-
til 1995 and then experience a slope of 0.157 timeij −
0.188(timeij − 5)+ until 2017. In other words, the breast
cancer mortality rate increased annually about 0.16 from
1990 to 1995 and then decreased by a factor of about 0.03
per year (0.157 - 0.0188 = 0.031) from 1996 to 2017.
In the final step of the data analysis, to investigate the
relationship between ASMR and HDI, the mean trend of
these rates was depicted by HDI level (Figure 2).
According to the mean ASMR trends in Figure 2, coun-
tries in each HDI level have their own intercept and slope
during the study time. Thus, we utilized four different
marginal models to estimate the mean trend of ASMR in
four levels of HDI. Because of the relatively linear nature
of the mean trends, the described linear marginal model
in the methods section was separately fitted for each HDI
level. Table 3 displays the obtained estimates from this
model.
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Table 1. Descriptive Statistics of Breast Cancer ASMR by HDI Level from 1990 to 2017
HDI
Year, Mean ± SD
1990 1995 2000 2005 2010 2015 2017
Low 13.86 ± 4.51 15.05 ± 4.82 15.73 ± 4.78 16.3 ± 5.15 16.71 ± 4.95 17 ± 4.38 17.03 ± 4.36
Medium 14.66 ± 6.03 15.58 ± 5.59 15.67 ± 5.88 15.82 ± 5.9 15.51 ± 5.36 16.44 ± 5.77 16.41 ± 5.92
High 21.62 ± 5.92 20.39 ± 6.26 19.38 ± 5.44 18.31 ± 5.31 17.83 ± 6.08 17.62 ± 6.67 17.33 ± 6.51
Very High 24.79 ± 6.40 25.05 ± 5.59 22.29 ± 5.50 20.36 ± 4.08 18.64 ± 3.93 17.55 ± 4.50 17.29 ± 4.61
Total 17.06 ± 6.80 17.67 ± 6.53 17.56 ± 5.95 17.51 ± 5.44 17.26 ± 5.26 17.21 ± 5.4 17.07 ± 5.39
Table 2. Parameter Estimates from Modeling the Mean Trend of Breast Cancer ASMR
in Total World Countries from 1990 to 2017
Parameter Estimate SE P Value
Intercept 17.01 0.48 < 0.001
Time 0.157 0.03 < 0.001




















































Figure 2. Mean trend of breast cancer ASMR by HDI level
According to Figure 2, the behavior of ASMRs for Low
and medium HDI countries is rather identical and also the
high and very high HDI countries have a nearly similar
trend. Therefore, we combined the countries with low and
medium HDI in a category and countries with high and
very high levels of HDI in another category. Figure 3 shows
the mean trend of breast cancer AMSR for these two cate-
gories. We also fitted the model (1) to these new categories
and the results are shown in the end rows of Table 3.
The estimates of intercepts and slopes in Table 3 sug-
gest that the countries with lower HDI (levels 1 and 2) have
Table 3. Parameter Estimates from Modeling the Mean Trend of Breast Cancer ASMR
for Different HDI Levels from 1990 to 2017
HDI Level Parameter Estimate SE P Value
Low
Intercept 14.39 0.69 < 0.001
Slope 0.11 0.03 < 0.001
Medium
Intercept 14.77 0.83 < 0.001
Slope 0.06 0.04 0.134
High
Intercept 21.01 1.11 < 0.001
Slope -0.16 0.06 0.008
Very high
Intercept 24.79 1.12 < 0.001
Slope -0.28 0.04 < 0.001
Low/medium
Intercept 14.67 0.59 < 0.001
Slope 0.08 0.03 0.003
High/very high
Intercept 23.04 0.94 < 0.001
Slope -0.23 0.04 < 0.001
a lower mean value of breast cancer mortality rate than
those with higher levels of HDI in the starting point of
the study (about 14 per 100,000 for countries in HDI lev-
els 1 and 2 versus about 21 for countries in HDI level 3 and
about 25 for countries in HDI level 4 in 1990). Despite lower
intercept estimates for the countries with lower levels of
HDI, these countries experienced an increasing trend dur-
ing these years (an annual increase of 0.11 per 100,000 for
countries in HDI level 1 and an annual increase of 0.06 per
100,000 for countries in HDI level 2). However, the wealth-
ier countries experienced downward trends in that period.
For countries in the HDI levels 3 and 4, respectively, an an-
nual decrease of 0.16 and 0.28 per 100,000 can be observed
between 1990 and 2017.
5. Discussion
According to the recent reports from worldwide data
sets, female breast cancer is one of the top three cancers in
terms of incidence and the fifth in terms of mortality. Fe-
male breast cancer together with lung and colorectal can-
4 Int J Cancer Manag. 2020; 13(8):e101813.


















































Figure 3. Mean trend of breast cancer ASMR for HDI level low/medium versus
high/very high
cers are responsible for about one-third of cancer mortal-
ity around the world. In addition, about 24% of all new
cases of cancer in women are diagnosed with breast can-
cer throughout the world. Breast cancer is also the lead-
ing cause of female cancer mortality (about 15% of cancer
deaths in women) (3, 12, 13).
In this study, we first investigated the global trend of
female breast cancer mortality rate for the period 1990 -
2017 using the GBD 2017 data. Our findings have revealed
that the global age standardized rate of death from breast
cancer was relatively stable between 1990 and 2017 (around
17 per 100,000). A trend analysis of breast cancer burden
by using the GLOBOCAN 2002 data has resulted in ASMR of
13.2 per 100,000 worldwide between 1993 and 2001 (rang-
ing from 8.8 in Asia to 19.7 in Europe) (9). The reported
findings from another study using GLOBOCAN 2012 data
have revealed that the age standardized mortality rate of
breast cancer for both sexes are 10.2, 16.1, 15.6, 17.3, and 12.9
per 100,000, respectively in Asia, Europe, Oceania, Africa,
and the whole world (17). In a research conducted on the
female breast cancer data from the GBD 2016 study for the
period 1990 to 2016 for 102 countries, the results have indi-
cated that deaths from this cancer increased from 336857
in 1990 to 535341 in 2016, however the breast cancer ASMR
decreased from 17.2 in 1990 to 14.6 per 100,000 females in
2016 (5). In the last decades, simple and free accessibility
to the data sets about the burden of different diseases in
nearly all world countries has provided the opportunity for
the researchers to report the point estimates of the bur-
den statistics and analyze the trend of these statistics in dif-
ferent world regions and time periods. Nevertheless, geo-
graphical and temporal variations, differences in utilized
indices, age or sex groups under the study, and discrep-
ancy in statistical analyses make the reported results in-
conclusive. In general, it seems that increasing the mor-
tality rate of breast cancer in countries with lower levels
of HDI nearly compensates for the reduction of the rate
in the countries with higher HDI levels and this makes the
global trend of breast cancer ASMR rather stable in the re-
cent decades (18).
The most important aim of the present study was to ex-
amine the longitudinal relationship between breast can-
cer ASMR and HDI. We have shown that while the coun-
tries with higher levels of development have a dramatically
downward trend for breast cancer mortality rate, coun-
tries with lower levels of development experience an up-
ward trend in these years. More specifically, our results
have indicated that although more developed countries
had higher levels of breast cancer mortality rates in the
starting point of the study (in 1990) than those with lower
HDI levels, the mean ASMR for all four levels of HDI were
nearly close together in the ending point of the study (in
2017), because of decreasing slope of ASMR for countries
with lower levels of HDI and increasing slope for those
with higher HDI levels. An overview of the published liter-
ature about the relationship between HDI and breast can-
cer mortality rates in different parts of the world showed
controversial findings. In most of these articles, the re-
searchers have utilized simple statistics (such as Pearson’s
correlation coefficient and simple linear regression) to as-
sess the relationship between breast cancer mortality rate
or breast cancer mortality-to-incidence ratio (MIR) and raw
values of HDI. For instance, Ghoncheh et al. have evalu-
ated the relationship between HDI and breast cancer mor-
tality in 2012. They have reported a non-significant corre-
lation of 0.091 and -0.051 between age-specific mortality
rate and HDI, respectively in the whole world countries and
Asia (10, 19). In another study in the Pan American region,
Martinez-Mesa et al. have reported a positive correlation of
0.44 between natural log age-standardized breast cancer
mortality rate and HDI in 2012 (20). As one of the most com-
prehensive studies in this field, Sharma has examined the
relationship between HDI and the burden of breast can-
cer in 2016. Using the data from GBD study 2016 (1990 -
2016) for 102 countries, he has remarked that the deaths
from breast cancer have doubled in 42% of the countries,
while the incidence of this disease has more than doubled
in 59% of 102 countries under the study in the period 1995
- 2016. Using the pairwise correlation coefficient, he has
also concluded that increasing HDI has resulted in a lower
mortality-to-incidence ratio in these countries. This latter
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finding shows the importance of development status in re-
ducing the burden of breast cancer and increasing the sur-
vival rate of the patients (5). In another study conducted
on GLOBOCAN database 2012 for 53 African countries, the
researchers have demonstrated that cancer mortality-to-
incidence rate inversely correlates with HDI (r = -0.897, P <
0.001). Using linear regression analysis, they have shown
that more than 80% of the variation in cancer mortality-
to-incidence could be explained by the variation in HDI
(beta = -0.898, adjusted R-square = 0.801). The high value
of the estimated R-square in the described study shows
the importance of promoting the economic status in con-
trolling the burden of cancer in this continent (21). Once
again, these controversial findings about the relationship
between the burden of breast cancer and HDI might be at-
tributed to the differences in choosing the statistical ap-
proach, geographical variation, sample size, or time period
of the study. Here, it should be noted that because both
the breast cancer mortality rate (or mortality-to-incidence
ratio) and HDI are time-varying indices, it is more con-
venient to utilize statistical approaches which enable us
to study the association between them more efficiently.
In the present study, we have used more advanced statis-
tical methods to capture the longitudinal nature of the
main outcome (breast cancer ASMR) and account for the
correlation between the outcome observations (repeated
measurements of ASMR for each country from 1990 to
2017). In other words, instead of summarizing the rela-
tionship between breast cancer ASMR and HDI using a sim-
ple univariate statistical index like Pearson’s or Spearman’s
correlation coefficient, we have modeled the longitudinal
behavior of the breast cancer ASMR, separately in each
level of HDI and evaluated the relationship between these
two statistics more formally. This advantage of our study
makes our results more reliable than those studies which
have used classic univariate statistical techniques for an-
alyzing their data. Lack of access to potential confound-
ing factors (such as the stage of breast cancer, age of cases,
completeness of cancer registry, and utilization of health
and treatment services) for all world countries during the
study period is one of the main limitations of our work. Ad-
justing these confounders in the modeling process might
lead to more reliable results and enhance the accuracy of
the estimates.
5.1. Conclusions
In conclusion, the findings of the present study re-
vealed a strong association between breast cancer mortal-
ity rate and development status, defined by HDI. In other
words, our findings imply that while breast cancer mor-
tality rates have been decreasing in high and very high
HDI countries since the early 90s, these rates continue to
increase in countries with low and medium HDI levels.
The decline in the wealthier countries might be attributed
to the diagnosis of the disease in the earlier stages, im-
prove the level of care. and access to the proper treatment
in these countries. On the other hand, the findings are
a serious alarm for health policymakers in the countries
with lower levels of development. To reduce the burden of
breast cancer in these countries, there is an urgent need for
promoting economic development, increasing awareness
about this cancer, establishing enhanced health care sys-
tems for the diagnosis of patients in the early stages, and
having access to necessary treatment.
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